Supportive Care in Cancer

, Volume 25, Issue 11, pp 3475–3483 | Cite as

Effectiveness of a standardized patient education program on therapy-related side effects and unplanned therapy interruptions in oral cancer therapy: a cluster-randomized controlled trial

  • C. Riese
  • B. Weiß
  • U. BorgesJr
  • A. Beylich
  • R. Dengler
  • K. Hermes-Moll
  • M. Welslau
  • W. Baumann
Original Article

Abstract

Purpose

Oral agents for cancer treatment are increasingly prescribed due to their benefits. However, oral cancer medications are difficult to handle and have a considerable potential for side effects. This type of therapy requires a high level of self-management competence by the patient. A standardized patient education program provided by physicians and oncology nurses may positively influence the handling of oral agents. The aim of the study was to evaluate the impact of a standardized patient education program provided by specially trained oncology nurses on therapy management regarding side effects and unplanned therapy interruptions.

Methods

One hundred sixty-five patients from 28 office-based oncology practices from all over Germany participated in this cluster-randomized controlled study. Patients of both intervention (n = 111) and standard care groups (n = 54) received the usual oncologist counseling; in addition, the patients from the intervention group (k = 17 practices) received an education from specially trained oncology nurses. The time of observation was 3 months per patient.

Results

The patients of the intervention group reported fewer side effects (skin rash, pain, fatigue, nausea, vomiting). Patients in the standard care group interrupted the therapy more frequently without informing their oncologist, compared to the intervention group.

Conclusions

Patients benefit from a standardized patient education program provided by specially trained oncology nurses. They tend to handle side effects and critical situations better.

Keywords

Oral cancer therapy Patient education Oncology nurses Therapy-related side effects Unplanned therapy interruption 

Notes

Acknowledgements

This research was funded by the German Federal Ministry of Health within the National Cancer Plan. We give special thanks to Klaus Becker, Patricia Bernhardt, Mathias Bertram, Hans Peter Böck, Maria Borrmann, Anita Breninek, Andrea Cazan, Hans Wilhelm Dübbers, Michael Eckart, Peter Ehscheidt, Ulrike Eichhorn, Alexandra Elflein, Till Oliver Emde, Birgit Euchenhofer, Regina Fey, Astrid Flöte, Werner Freier, Roswitha Fuchs, Stefanie Gawel, Thomas Hamm, Richard Hansen, Stefanie Heidtmann, Melanie Heinz, Anja Herbst, Alexandra Hesse, Jochen Heymanns, Ulrich Hutzschenreuter, Georg Jacobs, Semra Jäckel, Elke Janning, Sabine Kirchhoff, Nicole Kissel, Astrid Klein, Nicole Kratzer, Tanja Kreuzpaintner, Andrea Kretz, Carmen Lenz, Anja Liesegang, Albrecht Lindemann, Enno Moorahrend, Lothar Müller, Monika Müller, Constanze Priebe-Richter, Margret Rebmann-Albes, Tobias Reiber, Antje Reschke, Daniel Reschke, Annette Sauer, Michael Schauer, Susann Schleife, Stephan Schmitz, Ina Schoon, Monika Spanger, Jan Schröder, Petra Schwedhelm, Eveline Siegel, Daria Tisch, Eva Völkel, Dorothee Volgmann, Thomas Walawgo, Maria Weber, Monika Weiler, Linda Werner, Jochen Wilke, Merle Willam, Sarah Wolff, Mark-Oliver Zahn, and Pablo Zamora.

Compliance with ethical standards

Conflict of interest

The authors declare that there is no conflict of interest.

References

  1. 1.
    May P, Figgins B (2016) Oral anticancer therapy: a comprehensive assessment of patient perceptions and challenges. J Community Support Oncol:112–116Google Scholar
  2. 2.
    Shah N, Casella E, Capozzi D, McGettigan S, Gangadhar TC, Schuchter L, Myers JS (2015) Improving the safety of oral chemotherapy at an academic medical center. J Oncol Pract. doi:10.1200/JOP.2015.007260
  3. 3.
    Banna GL, Collova E, Gebbia V, Lipari H, Giuffrida P, Cavallaro S, Condorelli R, Buscarino C, Tralongo P, Ferraù F (2010) Anticancer oral therapy: emerging related issues. Cancer Treat rev 36(8):595–605CrossRefPubMedGoogle Scholar
  4. 4.
    Baumann, W (2014) Qualitätsbericht der onkologischen Schwerpunktpraxen 2014. BNHO – Berufsverband der Niedergelassenen Hämatologen und Onkologen 2015, KölnGoogle Scholar
  5. 5.
    Chihara D, Ito H, Matsuda T, Katanoda K, Shibata A, Saika K, Sobue T, Matsuo K (2012) Decreasing trend in mortality of chronic myelogenous leukemia patients after introduction of imatinib in Japan and the U.S. Oncologist 17(12):1547–1550CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Bordonaro S, Raiti F, Di Mari A, Lopiano C, Romano F, Pumo V, Giuliano SR, Iacono M, Lanteri E, Puzzo E, Spada S, Tralongo P (2012) Active home-based cancer treatment. J Multidiscip Healthc 5:137–143. doi:10.2147/JMDH.S31494 PubMedPubMedCentralGoogle Scholar
  7. 7.
    Overkamp F (2015) Herausforderungen zielgerichteter Substanzen an die onkologische Supportivtherapie. Onkologe 21:297–304. doi:10.1007/s00761-014-2795-y CrossRefGoogle Scholar
  8. 8.
    Riechelmann RP, Del Giglio A (2009) Drug interactions in oncology: how common are they? Ann Oncol 20:1907–1912. doi:10.1093/annonc/mdp369 CrossRefPubMedGoogle Scholar
  9. 9.
    Barth J, Schelenz C (2011) Orale Tumortherapie—DO’s and DON’Ts. Onkologische Pharmazie 13.3(2011):14–23Google Scholar
  10. 10.
    Schilder CM, Seynaeve C, Linn SC, Boogerd W, Beex LV, Gundy CM, Nortier JW, van de Velde CJ, van Dam FS, Schagen SB (2010) Cognitive functioning of postmenopausal breast cancer patients before adjuvant systemic therapy, and its association with medical and psychological factors. Crit Rev Oncol Hematol 76(2):133–141. doi:10.1016/j.critrevonc.2009.11.001 CrossRefPubMedGoogle Scholar
  11. 11.
    Molassiotes A, Brearley S, Saunders M, Craven O, Wardley A, Farrell C, Swindell R, Todd C, Luker K (2009) Effectiveness of a home care nursing program in the symptom management of patients with colorectal and breast cancer receiving oral chemotherapy: a randomized, controlled trial. J Clin Oncol 27:6191–6198. doi:10.1200/JCO.2008.20.6755 CrossRefGoogle Scholar
  12. 12.
    Birner A (2003) Safe administration of oral chemotherapy. Clin J Oncol Nurs 7:158–162. doi:10.1188/03.CJON.158-162 CrossRefPubMedGoogle Scholar
  13. 13.
    Miaskowski C, Shockney L, Chlebowski RT (2008) Adherence to oral endocrine therapy for breast cancer: a nursing perspective. Clin J Oncol Nurs 12:213–221. doi:10.1188/08. CJON.213-221 CrossRefPubMedGoogle Scholar
  14. 14.
    Kav S, Johnson J, Rittenberg C, Fernadez-Ortega P, Suominen T, Olsen PR, Patiraki E, Porock D, Dahler A, Toliusiene J, Tadic D, Pittayapan P, Roy V, Wang Q, Colak M, Saca-Hazboun H, Makumi D, Kadmon I, Ami SB, Anderson E, Clark-Snow R (2008) Role of the nurse in patient education and follow-up of people receiving oral chemotherapy treatment: an international survey. Support Care Cancer 16:1075–1083. doi:10.1007/s00520-007-0377-x CrossRefPubMedGoogle Scholar
  15. 15.
    Bordonaro S, Romano F, Lateri E, Cappuccio F, Indorato R, Butera A, D’Angelo A, Ferraú F, Tralongo P (2014) Effect of a structured, active, home-based cancer-treatment program for the management of patients on oral chemotherapy. Patient Preferences Adherence 8:917–923CrossRefGoogle Scholar
  16. 16.
    Chau I, Legge S, Fumoleau P (2004) The vital role of education and information in patients receiving capecitabine (Xeloda). Eur J Oncol Nurs 8(Suppl 1):41–53. doi:10.1016/j.ejon.2004.06.008 CrossRefGoogle Scholar
  17. 17.
    Temel JS, Greer JA, Muzikansky A, Gallagher ER, Admane S, Jackson VA, Dahlin CM, Blinderman CD, Jacobsen J, Pirl WF, Billings JA, Lynch TJ (2010) Early palliative care for patients with metastatic non–small-cell lung cancer. N Engl J Med 363:733–742. doi:10.1056/NEJMoa1000678 CrossRefPubMedGoogle Scholar
  18. 18.
    Campbell C (2016) An oral cancer therapy nurse navigator role. Canadian Nurse. https://www.canadian-nurse.com/en/articles/issues/2016/april-2016/an-oral-cancer-therapy-nurse-navigator-role. Accessed 12 July 2016
  19. 19.
    Adams G, Gulliford MC, Ukoumunne OC, Eldridge S, Chinn S, Campbell MJ (2004) Patterns of intra-cluster correlation from primary care research to inform study design and analysis. J Clin Epidemiol 57:785–794. doi:10.1016/j.jclinepi.2003.12.013 CrossRefPubMedGoogle Scholar
  20. 20.
    Kav S, Schulmeister L, Nirenberg A, Barber L, Johnson J, Rittenberg C (2010) Development of the MASCC teaching tool for patients receiving oral agents for cancer. Support Care Cancer 18:583–590. doi:10.1007/s00520-009-0692-5 CrossRefPubMedGoogle Scholar
  21. 21.
    Long JS, Freese J (2014) Regression models for categorical dependent variables using stata, Third edn. Stata Press Publication, StataCorp LP, College Station (Texas)Google Scholar
  22. 22.
    R Core Team (2016). R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. URL https://www.R-project.org/.
  23. 23.
    McCorkle R, Strumpf NE, Nuamah IF, Adler DC, Cooley ME, Jepson C, Lusk EJ, Torosian M (2000) A specialized home care intervention improves survival among older post-surgical cancer patients. J Am Geriatr Soc 48:1707–1713CrossRefPubMedGoogle Scholar
  24. 24.
    Haslbeck J (2008) Bewältigung komplexer Medikamentenregime aus Sicht chronisch Kranker. Pflege Gesellschaft 13(1):48–61Google Scholar
  25. 25.
    Basch E, Deal AM, Kris MG, Scher HI, Hudis CA, Sabbatini P, Rogak L, Bennett AV, Dueck AC, Atkinson TM, Chou JF, Dulko D, Sit L, Barz A, Novotny P, Fruscione M, Sloan JA, Schrag D (2015) Symptom monitoring with patient-reported outcomes during routine cancer treatment: a randomized controlled trial. Journal of Clinical Oncology JCO630830. doi:10.1200/JCO.2015.63.0830
  26. 26.
    Jatoi A, Rowland K, Sloan JA, Gross HM, Fishkin PA, Kahanic SP, Novotny PJ, Schaefer PL, Johnson DB, Tschetter LK, Loprinzi CL (2008) Tetracycline to prevent epidermal growth factor receptor inhibitor-induced skin rashes: results of a placebo-controlled trial from the North Central Cancer Treatment Group (N03CB). Cancer 113:847–853. doi:10.1002/cncr.23621 CrossRefPubMedPubMedCentralGoogle Scholar
  27. 27.
    Roila F, Herrstedt J, Aapro M, Gralla RJ, Einhorn LH, Ballatori E, Bria E, Clark-Snow RA, Espersen BT, Feyer P, Grunberg SM, Hesketh PJ, Jordan K, Kris MG, Maranzano E, Molassiotis A, Morrow G, Olver I, Rapoport BL, Rittenberg C, Saito M, Tonato M, Warr D, Group O behalf of the E.G.W (2010) Guideline update for MASCC and ESMO in the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting: results of the Perugia consensus conference. Ann Oncol 21:232–243. doi:10.1093/annonc/mdq194 CrossRefGoogle Scholar
  28. 28.
    Macedo LT, Lima JPN, dos Santos LV, Sasse AD (2014) Prevention strategies for chemotherapy-induced hand-foot syndrome: a systematic review and meta-analysis of prospective randomised trials. Support Care Cancer 22:1585–1593. doi:10.1007/s00520-014-2129-z PubMedGoogle Scholar
  29. 29.
    Wood L (2012) A review on adherence management in patients on oral cancer therapies. Eur J Oncol Nurs 16:432–438. doi:10.1016/j.ejon.2011.10.002 CrossRefPubMedGoogle Scholar
  30. 30.
    Miranda V, Fede A, Nobuo M, Ayres V, Giglio A, Miranda M, Riechelmann RP (2011) Adverse drug reactions and drug interactions as causes of hospital admission in oncology. J Pain Symptom Manag 42:342–353. doi:10.1016/j.jpainsymman.2010.11.014 CrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2017

Authors and Affiliations

  1. 1.Scientific Institute of Office-Based Hematologists and Oncologists—WINHOCologneGermany
  2. 2.Institute of SociologyUniversity of Duisburg-EssenDuisburgGermany
  3. 3.GESIS Leibniz Institute for the Social SciencesMannheimGermany
  4. 4.Hematological-Oncological Practice HOPAHamburgGermany
  5. 5.Hochschule für Oekonomie & Management (FOM)Institut für Gesundheit & Soziales (ifgs)MunichGermany
  6. 6.Hematological-Oncological PracticeAschaffenburgGermany

Personalised recommendations